Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAB NASDAQ:DRUG NASDAQ:EDIT NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACABAtlantic Coastal Acquisition Corp. II$5.77-47.1%$8.44$5.75▼$13.00$47.14M0.019,443 shs162,400 shsDRUGBright Minds Biosciences$26.16+0.7%$27.93$0.94▼$79.02$184.27M-6.01827,291 shs25,311 shsEDITEditas Medicine$2.76+1.1%$2.12$0.91▼$5.85$231.05M2.152.65 million shs2.54 million shsSLSSELLAS Life Sciences Group$1.77-6.8%$1.78$0.77▼$2.27$176.61M2.311.84 million shs2.86 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACABAtlantic Coastal Acquisition Corp. II0.00%0.00%0.00%0.00%-47.64%DRUGBright Minds Biosciences+0.65%+5.44%-7.20%-20.99%+2,116.95%EDITEditas Medicine+1.10%-4.17%+17.45%+114.79%-51.75%SLSSELLAS Life Sciences Group-6.84%-3.80%+12.74%+36.15%+60.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AN/AN/AN/ADRUGBright Minds Biosciences1.6626 of 5 stars3.62.00.00.00.02.50.0EDITEditas Medicine4.1566 of 5 stars3.22.00.04.33.22.50.6SLSSELLAS Life Sciences Group2.2022 of 5 stars3.51.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACABAtlantic Coastal Acquisition Corp. II 0.00N/AN/AN/ADRUGBright Minds Biosciences 3.13Buy$83.25218.23% UpsideEDITEditas Medicine 2.31Hold$4.7070.29% UpsideSLSSELLAS Life Sciences Group 3.00Buy$7.00295.48% UpsideCurrent Analyst Ratings BreakdownLatest ACAB, SLS, DRUG, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025SLSSELLAS Life Sciences GroupMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $7.007/2/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight5/21/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025DRUGBright Minds BiosciencesCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025DRUGBright Minds BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025DRUGBright Minds BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/13/2025EDITEditas MedicineRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$8.00 ➝ $4.005/7/2025DRUGBright Minds BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.004/29/2025EDITEditas MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/28/2025EDITEditas MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/A$0.92 per shareN/AEDITEditas Medicine$32.31M7.15N/AN/A$1.63 per share1.69SLSSELLAS Life Sciences Group$1M176.61N/AN/A$0.13 per share13.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACABAtlantic Coastal Acquisition Corp. IIN/AN/A0.00∞N/AN/AN/AN/AN/ADRUGBright Minds Biosciences-$2.06M-$0.36N/AN/AN/AN/A-14.56%-14.29%8/13/2025 (Estimated)EDITEditas Medicine-$237.09M-$3.04N/AN/AN/A-701.06%-139.24%-63.87%8/6/2025 (Estimated)SLSSELLAS Life Sciences Group-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)Latest ACAB, SLS, DRUG, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/ADRUGBright Minds Biosciences-$0.59N/AN/AN/AN/AN/A8/12/2025Q2 2025SLSSELLAS Life Sciences Group-$0.0767N/AN/AN/AN/AN/A8/6/2025Q2 2025EDITEditas Medicine-$0.40N/AN/AN/A$1.81 millionN/A5/15/2025Q2 2025DRUGBright Minds Biosciences-$0.39-$0.29+$0.10-$0.29N/AN/A5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/12/2025Q1 2025EDITEditas Medicine-$0.51-$0.43+$0.08-$0.92$0.79 million$4.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/ADRUGBright Minds BiosciencesN/AN/AN/AN/AN/AEDITEditas MedicineN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACABAtlantic Coastal Acquisition Corp. IIN/AN/AN/ADRUGBright Minds BiosciencesN/A126.01126.01EDITEditas MedicineN/A3.083.08SLSSELLAS Life Sciences GroupN/A4.644.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACABAtlantic Coastal Acquisition Corp. II23.30%DRUGBright Minds Biosciences40.52%EDITEditas Medicine71.90%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipACABAtlantic Coastal Acquisition Corp. II91.19%DRUGBright Minds Biosciences42.66%EDITEditas Medicine2.10%SLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACABAtlantic Coastal Acquisition Corp. II48.17 million720,000Not OptionableDRUGBright Minds BiosciencesN/A7.04 million4.04 millionNot OptionableEDITEditas Medicine23083.71 million81.96 millionOptionableSLSSELLAS Life Sciences Group1099.78 million98.38 millionNot OptionableACAB, SLS, DRUG, and EDIT HeadlinesRecent News About These CompaniesSELLAS Life Sciences Group (NASDAQ:SLS) Price Target Raised to $7.00July 16 at 3:14 PM | marketbeat.comSellas Flat on Trial SuccessJuly 16 at 6:14 AM | baystreet.caSELLAS gains as mid-stage trial for leukemia drug succeedsJuly 16 at 6:14 AM | msn.comSELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - NasdaqJuly 9, 2025 | nasdaq.comSELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% - Here's What HappenedJuly 9, 2025 | marketbeat.comSellas Life Sciences appoints Linghua Wang to Scientific Advisory BoardJuly 7, 2025 | msn.comSELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory BoardJuly 7, 2025 | globenewswire.comSELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® IndexesJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo FinanceJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?June 23, 2025 | zacks.comSellas Life Sciences: Tons Of Completed StudiesJune 17, 2025 | seekingalpha.comNostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) StockJune 14, 2025 | insidertrades.comSELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology ExpertsJune 5, 2025 | globenewswire.comSELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025June 4, 2025 | nasdaq.comSELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 SharesJune 3, 2025 | insidertrades.comSELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual MeetingJune 2, 2025 | globenewswire.comSELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company ShowcaseMay 20, 2025 | globenewswire.comSELLAS Life Sciences Group, Inc. Common StockMay 16, 2025 | fxempire.comFSellas doses first paediatric subject with AML in Phase II trial of SLS009May 16, 2025 | msn.comSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | finanznachrichten.deSELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AMLMay 15, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeWhy Hims & Hers Is a Buy Below $35 After Its 16% PullbackBy Gabriel Osorio-Mazilli | July 3, 2025View Why Hims & Hers Is a Buy Below $35 After Its 16% PullbackNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?ACAB, SLS, DRUG, and EDIT Company DescriptionsAtlantic Coastal Acquisition Corp. II NASDAQ:ACABAtlantic Coastal Acquisition Corp. II does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in financial services industry and mobility sector. The company was incorporated in 2021 and is based in New York, New York. Atlantic Coastal Acquisition Corp. II is a subsidiary of Atlantic Coastal Acquisition Management II LLC.Bright Minds Biosciences NASDAQ:DRUG$26.16 +0.17 (+0.65%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$26.27 +0.11 (+0.42%) As of 07/18/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.Editas Medicine NASDAQ:EDIT$2.76 +0.03 (+1.10%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.73 -0.03 (-1.09%) As of 07/18/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.SELLAS Life Sciences Group NASDAQ:SLS$1.77 -0.13 (-6.84%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
